美国 · 股市与财经 · Morningstar

New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

来源：Morningstar · 美国 18 小时前

NORTH CHICAGO, Ill., Oct. 11, 2026 /PRNewswire/ -- AbbVie today announced the presentation of 22 scientific abstracts from its market-leading inflammatory bowel disease (IBD)…

在 Morningstar 阅读全文登录后可收藏

MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.morningstar.com)

New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

推荐阅读

The investor’s guide to TechCrunch Disrupt 2026: Everything you need to know

Starknet coin surges as developer weighs Ethereum split over quantum security

For the first time ever, 10-year bond yields track diesel prices more closely than crude, and Trump’s fuel deal with Putin may be too little too late

Tokenized Stocks Show Real Demand But Remain Volatile and Illiquid, IMF Finds

From BJ’s to Lululemon, retailers are trimming assortments to boost business

Saylor teases Strategy Bitcoin buying after ending September with STRC buybacks

New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

分享

推荐阅读

The investor’s guide to TechCrunch Disrupt 2026: Everything you need to know

Starknet coin surges as developer weighs Ethereum split over quantum security

For the first time ever, 10-year bond yields track diesel prices more closely than crude, and Trump’s fuel deal with Putin may be too little too late

Tokenized Stocks Show Real Demand But Remain Volatile and Illiquid, IMF Finds

From BJ’s to Lululemon, retailers are trimming assortments to boost business

Saylor teases Strategy Bitcoin buying after ending September with STRC buybacks